The DEA's April 2026 final order moved state-licensed medical marijuana and FDA-approved marijuana products to Schedule III, while adult-use cannabis remained Schedule I. A subsequent administrative hearing on broader rescheduling from Schedule I to III ran from June 29 to July 15, 2026, with the DEA presenting evidence of accepted medical use drawn from the prior HHS scientific review. Closing briefs were filed in August, and the full transcript was released shortly after. On September 9, 2026, the D.C. Circuit rejected challenges seeking to stay the April order. Chief Administrative Law Judge Derek Julius is now preparing a recommendation for the DEA Administrator, whose final decision will determine the scope and timing of any further change. Ongoing litigation and the outcome of that recommendation remain the primary variables for market resolution.